Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results